Form 4: Ionis Pharmaceuticals CEO Brett P. Monia Sells Shares Under 10b5-1 Plan

Ionis Pharmaceuticals CEO Brett P. Monia sold 6,630 shares of common stock at a weighted average price of $38.0534, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Brett P. Monia, CEO of Ionis Pharmaceuticals, sold 6,630 shares of common stock on November 12, 2024.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2024.
• The shares were sold at a weighted average price of $38.0534.
• The transactions occurred at prices ranging from $37.73 to $38.655.
• Following the transaction, Monia directly owns 167,393 shares of Ionis Pharmaceuticals stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine disclosure of an executive stock sale under a pre-arranged trading plan, which is common practice for corporate insiders to avoid accusations of trading on non-public information. It is not unusual for executives to sell shares for personal financial management.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors, such as Amgen, Gilead Sciences, and Biogen.
• These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The reported transaction is consistent with typical executive stock sales in terms of volume and price range.

Stakeholder Impact

• The stock sale may have a minor impact on the stock price, but it is unlikely to be significant given the pre-arranged nature of the transaction.

Key Dates

Keywords

Ionis Pharmaceuticals, Brett P. Monia, stock sale, 10b5-1 trading plan, insider trading, executive stock transaction